Elsevier

Clinical Therapeutics

Volume 24, Issue 3, March 2002, Pages 460-467
Clinical Therapeutics

Brief report
Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy

https://doi.org/10.1016/S0149-2918(02)85047-0Get rights and content

Abstract

Background: Although medication adherence is one of the most important aspects of the management of diabetes mellitus, low rates of adherence have been documented.

Objective: This study sought to examine medication adherence among patients with diabetes mellitus in a managed care organization who were receiving antidiabetic monotherapy (metformin or glyburide), combination therapy (metformin and glyburide), or fixed-dose combination therapy (glyburide/metformin).

Methods: Medication adherence was evaluated through a retrospective database analysis of pharmacy claims. The adherence rate was defined as the sum of the days' supply of oral antidiabetic medication obtained by the patient during the follow-up period divided by the total number of days in the designated follow-up period (180 days). Health plan members were included in the analysis if they had an index pharmacy claim for an oral antidiabetic medication between August 1 and December 31, 2000, were continuously enrolled in the health plan, and were aged ≥18 years. A 6-month pre-index period was used to classify patients as newly treated or previously treated. Patients were grouped according to their medication-use patterns.

Results: After adjustment for potential confounding factors, including overall medication burden at index, there were no significant differences in adherence rates among 6502 newly treated patients receiving monotherapy, combination therapy, or fixed-dose combination therapy. Among the 1815 previously treated patients receiving glyburide or metformin monotherapy who required the addition of the alternative agent, resulting in combination therapy, adherence rates were significantly lower (54.0%; 95% CI, 0.52–0.55) than in the 105 patients receiving monotherapy who were switched to fixed-dose combination therapy (77.0%; 95% CI, 0.72–0.82). The 59 previously treated patients receiving combination therapy who were switched to fixed-dose combination therapy had a significant improvement in adherence after the switch (71.0% vs 87.0%; P < 0.001).

Conclusions: In a managed care organization, previously treated patients receiving monotherapy with an oral antidiabetic medication who required additional therapy exhibited significantly greater adherence when they were switched to fixed-dose combination therapy compared with combination therapy. Patients receiving combination therapy who were switched to fixed-dose combination therapy exhibited significantly greater adherence after the switch.

References (8)

  • M Von Korff et al.

    A chronic disease score from automated pharmacy data

    J Clin Epidemiol

    (1992)
  • Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/diabetes/pub/glance/htm#dcp....
  • Diabetes facts and figures. American Diabetes Association Web site. Available at:...
  • PF Adams et al.

    Current estimates from the National Health Interview Survey, 1989

    Vital Health Stat 10

    (1990)
There are more references available in the full text version of this article.

Cited by (208)

  • A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy

    2019, Diabetes Research and Clinical Practice
    Citation Excerpt :

    However, the rate of compliance in the combined use of two or more oral hypoglycemic agents by T2DM patients for an unspecified duration, one of the most common causes of poor glycemic control by T2DM patients who need combination therapy, has been found to be relatively low. Therefore, administration of a composite drug of two oral hypoglycemic agents as a more convenient form of medication can be an effective alternative method for improving patient compliance and thus ensuring long-term glycemic control [5,19,20]. Developing a therapy that combines administration of oral hypoglycemic agents and insulin therapy was proposed as a means of eliciting the synergistic effect of each agent’s complementary mechanisms.

View all citing articles on Scopus
View full text